These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121 [TBL] [Abstract][Full Text] [Related]
3. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526 [TBL] [Abstract][Full Text] [Related]
4. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. Grosso JF; Herbert LM; Owen JL; Lopez DM J Immunol; 2004 Aug; 173(3):1721-30. PubMed ID: 15265901 [TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800 [TBL] [Abstract][Full Text] [Related]
6. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Soares MM; Mehta V; Finn OJ J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807 [TBL] [Abstract][Full Text] [Related]
7. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. Koido S; Tanaka Y; Chen D; Kufe D; Gong J J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096 [TBL] [Abstract][Full Text] [Related]
8. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607 [TBL] [Abstract][Full Text] [Related]
11. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Dezfouli S; Hatzinisiriou I; Ralph SJ Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812 [TBL] [Abstract][Full Text] [Related]
13. Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856 [TBL] [Abstract][Full Text] [Related]
14. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. Park SH; Kyin T; Bendelac A; Carnaud C J Immunol; 2003 Feb; 170(3):1197-201. PubMed ID: 12538676 [TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Kelly JM; Darcy PK; Markby JL; Godfrey DI; Takeda K; Yagita H; Smyth MJ Nat Immunol; 2002 Jan; 3(1):83-90. PubMed ID: 11743585 [TBL] [Abstract][Full Text] [Related]
16. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells. Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292 [TBL] [Abstract][Full Text] [Related]
17. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044 [TBL] [Abstract][Full Text] [Related]
18. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956 [TBL] [Abstract][Full Text] [Related]
19. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. Li Y; McGowan P; Hellström I; Hellström KE; Chen L J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929 [TBL] [Abstract][Full Text] [Related]
20. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Barratt-Boyes SM; Vlad A; Finn OJ Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]